ASCL1 and neuroblastoma: Although other factors have been described to modulate RA differentiation in neuroblastoma, hASH1 represents a unique target and a possible biomarker for all neuroblastoma, independent of MYCN amplification status (Shah et al., 2014; Cimmino et al., 2015; Heynen et al., 2016).